What is the Diagnostic Consortium to Advance the Ecosystem for Hereditary Angioedema (DISCOVERY)?
The prevalence of hereditary angioedema (HAE), one of the rare diseases, in Japan is said to be 1 in 50,000,
and there is a report that there are about 430 patients under diagnosis and treatment in Japan,
which is only 20% of the estimated number of patients in Japan.
In addition, there is a large gap in the average time from initial onset to diagnosis
(13.8 years in Japan, less than 10 years in Europe and the United States) compared to Europe and the United States.
In order to save patients suffering from undiagnosed HAE,
the consortium will collaborate with medical professionals, academic societies, patient groups,
and pharmaceutical companies, IT companies who deal with HAE patients on a daily basis,
and aim to improve the appropriate early diagnosis and diagnosis rate through their expertise and creativity.